Pretreatment angiogenic cytokines predict response to chemoimmunotherapy in patients with chronic lymphocytic leukaemia.
Serum levels of pro-[vascular endothelial growth factor (VEGF)] and anti-[thrombospondin-1 (TSP)] angiogenic cytokines were prospectively measured in a phase II trial of chemoimmunotherapy (CIT) for chronic lymphocytic leukaemia (CLL) patients (n = 56). Pretreatment VEGF levels were lower among patients who achieved complete remission (CR) or nodular partial remission (nPR) relative to those with partial remission (PR) or stable/progressive disease (median 122.0 pg/ml vs. 246.8 pg/ml; P = 0.03). VEGF:TSP ratio was lower (anti-angiogenic phenotype) among patients who achieved CR/nPR. The pretreatment VEGF:TSP ratio also correlated with overall survival (P = 0.008). A pro-angiogenic profile appears associated with diminished response and inferior survival in CLL patients receiving CIT.
Shanafelt
Tait D
TD
Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA. shanafelt.tait@mayo.edu
Byrd
John C
JC
LaPLant
Betsy
B
Zent
Clive S
CS
Call
Tim
T
Secreto
Charla
C
Grever
Michael R
MR
Lin
Thomas S
TS
Kay
Neil E
NE
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D005346:Fibroblast Growth Factors / Q000097:blood*; D006801:Humans; D007167:Immunotherapy; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000097:blood* / Q000628:therapy; D015649:Pentostatin / Q000627:therapeutic use; D011379:Prognosis; D011446:Prospective Studies; D000069283:Rituximab; D019700:Thrombospondin 1 / Q000097:blood*; D042442:Vascular Endothelial Growth Factors / Q000097:blood*
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D019700:Thrombospondin 1; D042442:Vascular Endothelial Growth Factors; D015649:Pentostatin; D000069283:Rituximab; D005346:Fibroblast Growth Factors; D003520:Cyclophosphamide